Cardiac Amyloidosis As a Reason for Heart Failure Exacerbation Among Older Adults: The Impact of its Increasing Diagnosis in PALTC

#### David Wolinsky, MD, FACC, MASNC

Director, Cardiac Amyloid Center Section Head Nuclear Cardiology Cleveland Clinic Florida Past President, American Society Nuclear Cardiology

1

#### **Disclosures**

Pfizer: Speaker, ConsultantAlnylam : Consultant, Speaker

BridgeBio: ConsultantIonis: Grant reviewer

• Astellas: Speaker (inactive)

2



## **Learning Objectives**

- Understand that amyloidosis has a broad range of clinical manifestations that makes recognition difficult
- Identify which cardiac patients have signs or symptoms consistent with cardiac amyloidosis
- Learn indications for non-invasive testing for cardiac amyloid and how to interpret results
- Understand the value of early diagnosis on treatment options and prognosis


Q1. Which inheritedTTR gene variant is present in 3-4 of AfroAmericans is the most common in the US  1. Thr(60)Ala (T60A) 2 Val MET 30(V30M) 3. Val122le (V122) 4. Ike68Leu (I68L)	
4	
Q2 Other than Endomyocardial Biopsy, Which of the Following Tests can be considered Diagnostic of wATTR	
CMR with increased ECV and Increased thickness	
Grade 3 PYP scan with negative clonal testing	
<ul> <li>Grade 2 Pyp scan with elevated ntBNP and hs Troponin</li> </ul>	
<ul> <li>ECHO showing increased left ventricular thickness and abnormal longitudinal strain</li> </ul>	
5	
Q3.	
* 3. You suspect cardiac amyloidosis based on heart failure and history of bilateral carpal tunnel syndrome.  Echocardiogram shows classic findings with left ventricular wall thickening and abnormal longitudinal strain with an apical sparing pattern. Serum free light chain assay was abnormal with elevated Kappa light chains, normal	
lambda light chains and a highly abnormal Kappa to lambda ratio. The patient's renal function was normal. The next best test to perform is:	
<ul><li>1) Cardiac Magnetic Resonance-CMR</li><li>2) Endomyocardial biopsy</li></ul>	
• 3) 99mTC-PYP imaging	
4) TTR genetic test	
5) No further testing needed	

<ul> <li>Q4. A 77yoman with HFpEF has an echo suspicious for cardiac amyloidosis. He has a history of bilateral carpal tunnel surgery. Which test of the following would you order?</li> <li>1) Tc- PYP scan, SPEP, UIEP</li> <li>2) Serum light chains and serum and urine immunoelectrophoresis</li> <li>3) CMR</li> <li>5) Tc-99m PYP scan with serum and urine electrophoresis</li> </ul>	
7	
	1
A Sad Story	
<ul> <li>76 yo Afro-Caribbean male with history of</li> </ul>	
pacemaker 5 yrs prior. NO hx DM, HTN, CAD	
Saw Cardiologist two months prior.	
"Everything was good."	
<ul><li>Stress test negative</li><li>ECHO EF 48%, Bi-atrial enlargement</li></ul>	
Moderate concentric LVH	
3	
	1
WW	
****	
<ul> <li>Presented to ER abdominal pain, 20 pound weight loss, SOB, inability to walk</li> </ul>	
Long history of numbness in hands and	
toes.	
<ul> <li>Attributed to cervical and lumbar radiculopathy</li> </ul>	
<ul> <li>Progressive decrease in ability to walk</li> </ul>	


# WW - Data BAse

- BUN/CR =28/1.2
- Nt-BNP 3200
- Tn 0.66
- EF 38%

10



11



### **Clinical Impression**

- Heart failure chronic diastolic
- Profound weakness and ambulatory limitation -refer to Neurology
- Weight loss, cachexia refer to GI
- No testing to evaluate etiology of cardiac disease

13

## Neurology

- HX of C-spine fusion
- · Bilateral arm weakness
- · Atrophy of hand muscles
- Carpal tunnel
- Spine CT order, PT
- No other diagnostic test
- No explanation why he could not walk

14

#### Gastroenterology

- Mild weight loss possibly due to systolic heart failure
- Suggest nutritional support ENSURE
- No workup or testing

# **Neurosurgery Consult**

- Bilateral neuroforaminal spinal stenosis
- Not a candidate for surgery due to EF 38%


16

#### Returned to ER Six Weeks Later

- Weaker , SOB, unable to swallow , unable to walk without use of walker
- ECG = new Afib
- ECHO= EF 20%
- Imaging for Amyloid
- Genetic testing

17

#### **PYP Planar**



Cardiac Uptake greater than contralateral bone

Genetic Testing=

#### Transferred to Subacute Rehab


- Returned to ER after two weeks fluid overload and weak
- Hospitalized x 10 days
- Transferred to nursing home
- Died in hospice 6 weeks later

19

#### Summary

- Chronic Diastolic Heart Failure-Progression to systolic
- Paroxysmal Atrial Fibrillation
- Abnormal ECG- Low voltage
- Abnormal ECHO LVH, Bi-atrial enlargement
- Peripheral Neuropathy
- Edema
- GI Symptons –
- Bilateral CTS, spinal stenosis
- Weight loss and Cachexia

Amyloidosis



20

## A Long Story with a Good Ending

A		— Initial
	"A person living with HIV has a similar life expectancy to	
Henry Masu	an HIV-negative person – providing they are diagnosed	nan, M.D., Gary Worn
	in good time, have good access to medical care, and	
Article	are able to adhere to their HIV treatment."	
	PON MARKETINE	05:1431-1438 IM198112103052402
35 References	790 Citing Article Control of Con	M170112103032402

# Clinician Understanding of Amyloid CCF Pilot Study

#### Results

	Not Confident	Somewhat Confident	Moderately Confident	Very Confident
How confident are you in diagnosing ATTR-CM?	52 (59.1)	19 (21.6)	9 (10.2)	8 (9.1)
How confident are you in <b>differentiating</b> the types of ATTR-CM?	68 (77.3)	8 (9.1)	6 (6.8)	6 (6.8)
How confident are you in <b>identifying the clinical presentations</b> of ATTR-CM (such as $\underline{\text{HSg(f)}}$ ?	40 (45.5)	23 (26.1)	15 (17.0)	10 (11.4)
How confident are you in identifying the soft tissue signs and symptoms of ATTR-CM (such as fumbar stenosis)?	49 (55.7)	21 (23:9)	13 (14.8)	5 (5.7)
How confident are you in <b>Identifying the GI signs and symptoms</b> of ATTR-CM (such as early satiety)?	52 (59.1)	21 (23:9)	10 (11.4)	\$ (5.7)
How confident are you in <b>Identifying the neurologic sign and symptoms</b> of ATTR-CM (such as carpal tunnel syndrome)?	47 (53.4)	20 [22.7]	11 (12.5)	10 (11.4)
How confident are you with nuclear scintigraphy?	56 (63.6)	22 (25:0)	4 (4.5)	6 (6.8)
How confident are you with endomyocardial biopsy?	57 (64.8)	16 (18.2)	10 (11.4)	5 (5.7)
How confident are you with <b>genetic testing</b> to determine if ATTR-CM is hereditary?	59 (67.0)	15 (17 0)	8 (8.1)	6 (6.8)
How confident are you in differentiating between light chain amyloidesis (AL) and ATTR-CM?	54 (61.4)	16 (18.2)	11 (12.5)	7 (8.0)

Wolinsky, D and Sarkar, A Submitted for Publication

22

# ACC Expert Comments contained and a second product of the Comments conta

Diamond J .Curr Treat Options Cardio Med (2022) 24:199.

- 6,000,000 Americans have Heart failure
- More than 1,000,000 hospitalizations per year
- 25% return in 30 days
- 50% return in 6 mo
- 700,000- new cases per year Half of them HFpEF
- HOSPITALIZATION IS A SENTINAL EVENT
- Recurrent hospitalizations are associated with increased mortality

Huusko ESC Heart Failure 2020; 7: 2406–2417


23

# Figure 1. Incidence par 1,000 person-years Preserved on, Reduced Epertum Proclams \*\*Transport Only 1. \*\*T

# Classification of Heart Failure AHA/ACC Stages A, B C, D NYHA Class I, II, III, IV Advanced HF

Roger V. Circulation Research. 2021;128:1421-1434.


25





26

#### What is amyloid?

- Amyloid is a protein folding disorder leading to the deposition of insoluble amyloid fibrils in the heart and other tissues
  - R. Virchow, 1854
- Amyloid is a systemic disease
- Name derived from Latin amylum (starch)
- Histological diagnosis aggregates of  $\beta\text{--sheets}$  that stain with Congo Red (green birefringence)








#### Delayed Diagnosis of CA

- Time from Initial Sx → Dx is unacceptably high
  - AL-CA: 2 years, ~1/3 visited >5 physicians before Dx
  - ATTR-CA: there was a 3-year (median) delay in diagnosis (ATTR) amyloidosis.



Bishop, Emily E. (2018) Amyloid, DOI: <u>10.1080/13506129.2018.1498782</u> Maurer Circulation q2017;135:1357-1377.

Lousada et al., Adv Ther, 2015)

31

#### Prevalence wATTR

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction ©

#### Conclusion

ATTRwt is an underdiagnosed disease that accounts for a significant number (13%) of HFPEF cases. The effect of emerging TTR-modifying drugs should be evaluated in these patients.

32

#### We Cannot Afford Not to Look for and Treat ATTR-CA

#### **Heart Failure With Preserved Ejection Fraction**


Time for a Reset


Katherine A. A. Clark, MD, MBA<sup>1</sup>; Eric J. Velazquez, MD<sup>1</sup>

⇒ Author Affiliations

JAMA. 2020;324(15):1506-1508. doi:10.1001/jama.2020.15566


Of the estimated 5 million patients in the US diagnosed with heart failure (HF), approximately 50% have HF with preserved ejection fraction (HFpEF), 1,2 and its prevalence is increasing by about 1% annually relative to that of heart failure with reduced ejection fraction (HFrEF).<sup>3</sup> The mortality associated with HF is substantial, and HF was estimated to account for more than 80 000 deaths annually in the US as of 2017.<sup>4</sup> In addition, because HF is projected to account for an estimated \$69.8 billion in annual health care spending by 2030, HFpEF represents an important public health issue that will increase as the population ages, with a concurrent increasing prevalence of associated risk factors, including hypertension, obesity, and diabetes.<sup>4</sup>








- Why do States with Highest Black Populations Have the Lowest Death Rates Due to Amyloid?
- Failure to Evaluate-Diagnose


35












# Orthopedic Abnormalities

- 10% of pts with bilateral carpal tunnel syndrome have ATTR
- 50% of ATTR patients have Bilateral CTS
- Up to 1/3 of patients undergoing spinal stenosis stain positive for amyloid
- Trigger finger
- Multiple joint replacement
- · History rotator cuff surgery

Nativi-Nicolai, J. Heart Failure Reviews (2022) 27:785-793Nicolai.

41

# GI Manifestations ATTR Texts 1. Explained and desired activation of the Regular authorization of the R



# Most Common Confounding Diagnoses

- Hypertensive heart disease
- Hypertrophic Cardiomyopathy -40 % of LV increased thickening in A TTR-CMmay be asymmetric.
- Five percent of HOCUM patients may also have cATTR
- Infiltrative Cardiomyopathy
- Aortic Stenosis 14% patients presenting for TAVR also have ATTR -CM

44

# What is the "typical" ECG pattern cardiac Amyloid







Figure 1. ECG of a patient with cardiac AL amyloidosis short small QRS voltages (defined as ≤6 mm height), predominantly in limb leads and pseudoinfarction pattern in the anterior leads.

### Commonest ECG Findings



- Low Voltage present in 40%
- Associated with advanced disease
- Lack of low voltage should not dissuade amyloid workup in appropriate patient

46

#### Clues to Cardiac Amyloid - LVEF

- HFpEF- But usually mildly reduced LVEF.
- Typical EF 45-50%.
- HFrEF 30-45% does not preclude consideration of amyloid
- Severe LV dysfunction EF 10-25% unusual in absence of severe disease
- Increase LV thickness on ECHO without LVH on ECG

47


## Electrophysiologic Findings

- Refractory atrial fibrillation- multiple cardioversions and ablations
- RBBB with first degree A-V block or LAHB
- · Intolerance to RV pacing
- Clinical deterioration in setting of rhythm management

Rappezzi C. Circulation. 2009;120:1203-1212

#### Clinical-hemodynamics- Low Output Low- normal BP in setting of prior hypertension

ACE/ARB and Beta Blockers in TTR Amyloid







49

# Diagnostic Workup

50

# "Gold Standard"-Endomyocardial Biopsy









#### Cardiac Amyloidosis - Echo Suspician



- Echo Findings:

   Biventricular ↑ wall thickness


   "Granular sparkling pattern"

   ↑ RA and LA size / dyfn / stasis

   Mechanically silent Atria

- Thickened valves / atrial septum
- Pericardial effusion
- Pulmonary HTN
- Low stroke volume
- Abnormal diastolic function

52



53


## What is Strain?

= tissue deformation as a function of applied force

= relative change of length of an object (e.g. myocardial fiber)


\*\*\*\*\*\*\* L0 = initial length L = compressed length Strain =  $(L - L_0)/L_0$ 

Strain Rate= rate of change





# Apical Sparing



55

#### **ECHO**

- Suggestive not diagnostic or pathognomic
- Not all patients with typical echo findings have amyloid
- Not all patients with amyloid have all the echo findings
- CANNOT PRESCRIBE THERAPY BASED ON ECHO ALONE
- SUGGESTIVE ECHOES NEED FOLLOWUP

56

#### **Fat Pad Aspirate Poor Test for ATTR**


- Sensitivity for AL amyloid of 70 % at best
- Positive in < 50 % of subjects with TTR cardiac amyloid



## Potential Utility of CMR in Cardiac Amyloidosis

- 1. Increase suspicion of presence of disease
- Diffuse late enhancement that can either be subendocardial or transmural, that does not follow coronary distribution,
- poor myocardial signal nulling on PSIR LGE sequence
- Marked increase in extracellular volume (>40%) or native (non-contrast) T1
   Confers prognostic value
- - Transmural or high ECV, worst prognosis
    Absence of LGE, best prognosis
- 6. Serial imaging for response to therapy


58





59

#### Tc-PYP Scan

- PYP is calcium avid
- Bone imaging agent
- 1970's used to diagnose acute myocardial infarction
- Mechanism for binding to amyloid tissue unclear








# Table 1. Accuracy of Tip preplanellum seam for descring ATTR Cardiac sumpleatable lead operations and quantitative and quant


	im and Orine Tests to Kuu	Out AL Amyloid	osis"		
Test	What Does it Detect?	Most Sensi	tive Test for:	Normal Range	
SPIET	Clonal immunoglobulin and/or clonal light chair	Confirming clon immunoglob	all oulin production	No M-spike present	<ul> <li>With age Kappa Levels</li> </ul>
	Clonal immunoglobulin and/or clonal light chair			No M-spike present	increase
Serum free light chain assay	Ratio of serum kappa:lambo light chains	chain produc	evel clonal light ction; clonality atio is far from 1:	Kappa:lambda ratio = 0.26-1.651	With decreasing GFR
					=>0.48-3.38
TABLE 3 No	ermal Values of Commonly	v Used sFLC Assa	vs		
TABLE 3 No	rmal Values of Commonb	y Used sFLC Assa Lambda	ys sFLC Ratio	Renal Range*	=>0.48-3.38 • With GFR< 30-→0.54-3.30
				Renal Range*	=>0.48-3.38
Assay				Renal Range*	=>0.48-3.38 • With GFR< 30-→0.54-3.30 • Ratio increases because of
Assay	Карра	Lambda	sFLC Ratio		=>0.48-3.38 • With GFR< 30-→0.54-3.30 • Ratio increases because of increased urinary spillage of
Assay Freelite mg/dl†	0.33-1.94 3.3-19.40	Lambda 0.57-2.63	sFLC Ratio		=>0.48-3.38 • With GFR< 30-→0.54-3.30 • Ratio increases because of increased urinary spillage of
Assay Freelite mg/dl† mg/l	0.33-1.94 3.3-19.40	Lambda 0.57-2.63	sFLC Ratio		=>0.48-3.38 • With GFR< 30-→0.54-3.30 • Ratio increases because of



65

# Management

 The treatment of Heart Failure in patients with cardiac amyloidosis differs from the therapy generally recommended in patients with diastolic or systolic heart failure



# Venticular Interdependence: Diastole Ventricular Interdependence: Diastole Increased for in one ventricle docreases the other ventricles compliance

68

#### **Diuretics**

- Diuretic Use Torsemide, Bumetanide, They have better intestinal absorption
- PRN metolazone- do not delay- start with 3-5 lb weight gain
- Spironolactone + loop diuretic is generally well tolerated
- Adjust diuretics based on clinical status
- IV diuretics: Use with close monitoring as it may result in progressive azotemia and hypotension

## Management

- Avoid ACE,ARB,ARNI:

  - Safety and efficacy is uncertain (no clinical trials)
     May provoke profound hypotension in AL amyloidosis (possibly by exposing a subclinical autonomic neuropathy)
     Better tolerated in TTR amyloid (wild type)
- · Avoid digoxin:
  - Amyloid fibrils bind to it and this interaction may increase risk for digitalis toxicity

#### ARNI

No concrete data


70

#### Management





71


#### ACE/ARB and Beta Blockers in Cardiac Amyloid





F. aus dem Siepen, ISA 2016
























Polyr	Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial							
> Author Aff	John L. Berk, MD <sup>1</sup> ; Ole B. Suhr, MD, PhD <sup>2</sup> ; Laura Obici, MD <sup>3</sup> ; <u>et al</u> ⇒ Author Affiliations   Article Information  JAMA. 2013;310(24):2658-2667. doi:10.1001/jama.2013.283815			of diflunisal com impairment and	pared with preserved of	placebo for 2 quality of life	patients with familial amyloid polyneuropathy, the use 2 years reduced the rate of progression of neurological . Although longer-term follow-up studies are needed, atment for familial amyloid polyneuropathy.	
TTR stabilizers								
Tofamids	FDA approved for ATTRust-CM and ATTRu-CM	20*, 61, or 80 mg once daily	ATTI-ACT trail* Inclusion: End-distribic septial thickness >12 mm History of heart failure NE-groRN2-EGO ppind, Exclusion: GANYT <100 m NYNA class in frymptoms Loer or heart transplantation eGR <2.5 mL, emin*-1.73 m²	None n	None	\$225 000vy	Caveats:	
Diffunical	FDA approved as NSAID Off-label use in ATTRv4 or ATTRv with neuropathyl cantiomyopathyl	250 mg orally twice daily Administer with proton pump inhibitor	Dribunial fisid Consortium <sup>34</sup> Inclusion: ATTRI with sensormotor polyneuropathy (tamilal amploid polyneuropathy) (tamilal amploid polyneuropathy) deposits Confirmed Timilation: Exclusion: NYHA Class M symptoms Estimated creatmine clearance - 100 millionis	Fluid retention Renal dysfunction Bleeding	Renal function Platelet count Hemoglobin	*\$60tmo	AntiCoagulation	












#### **PROGNOSIS**


86


# Stagging Systems ATTR Mayo and Gilmour (NAC) Table 1 Clinical staging systems for transthyretia annyloid cardiomyopathy Gregon et ed., 2018 (Hayo') ATTRest ATTR and ATTREST Stage Separameters Stage (All Control of Con














Q1. Which inheritedTTR gene variant is present
in 3-4 of AfroAmericans is the most common in
the US

- 1. Thr(60)Ala (T60A)
- 2 Val MET 30(V30M)
- 3. Val122le (V122)
- 4. lke68Leu (I68L)

# **Cardiac Amyloid**

• If you don't think of looking for it , you won't find it



But if you find it You can help

95

Q1. Which inherited TTR gene variant is present in 3-4 of Afro-Americans is the most common in the US

- 1. Thr (60)Ala (T60A)
- 2 Val MET 30(V30M)
- 3. Val122le (V122)
- 4. lke 68Leu (I68L)

Q1. Which inherited TTR gene variant is present in 3-4 of Afro-Americans is the most common in the US	
<ul> <li>1. Thr (60)Ala (T60A)</li> <li>2 Val MET 30(V30M)</li> <li>3. Val122le (V122)</li> <li>4. Ike 68Leu (I68L)</li> </ul>	
97	
Q2 Other than Endomyocardial Biopsy, Which of the Following Tests can be considered Diagnostic of wATTR	
CMR with increased ECV and Increased	
<ul><li>thickness</li><li>Grade 3 PYP scan with negative clonal testing</li></ul>	-
Grade 2 PYP scan with elevated ntBNP and hs Troponin	·
ECHO showing increased left ventricular	
thickness and abnormal longitudinal strain	
98	
Q2 Other than Endomyocardial Biopsy, Which of the Following Tests can be considered Diagnostic of wATTR	
CMR with increased ECV and Increased	
<ul><li>thickness</li><li>Grade 3 PYP scan with negative clonal testing</li></ul>	
Grade 2 PYP scan with elevated ntBNP and hs     Troponin	
ECHO showing increased left ventricular	·
thickness and abnormal longitudinal strain	
99	

•	`	$\boldsymbol{\gamma}$	
(	)	≺	
`	¥	J	١

\* 3. You suspect cardiac amyloidosis based on heart failure and history of bilateral carpal tunnel syndrome. Echocardiogram shows classic findings with left ventricular wall thickening and abnormal longitudinal strain with an apical sparing pattern. Serum free light chain assay was abnormal with elevated Kappa light chains, normal lambda light chains and a highly abnormal Kappa to lambda ratio. The patient's renal function was normal. The nebest test to perform is:

- 1) Cardiac Magnetic Resonance-CMR
- 2) Endomyocardial biopsy
- 3) 99mTC-PYP imaging
- 4) TTR genetic test
- 5) No further testing needed

100

#### Q3.

\*3. You suspect cardiac amyloidosis based on heart failure and history of bilaterial carpal tunnel syndrome. Echocardiogram shows classic findings with left ventricular wall thickening and abnormal longitudinal strain with an apical sparing pattern. Serum free light chain assay was abnormal with elevated Kappa light chains, normal lambda light chains and a highly abnormal Kappa to lambda ratio. The patient's renal function was normal. The ne best test to perform is:

- 1) Cardiac Magnetic Resonance-CMR
- 2) Endomyocardial biopsy
- 3) 99mTC-PYP imaging
- 4) TTR genetic test
- 5) No further testing needed

101

Q4. A 77yo man with HFpEF has an echo suspicious for cardiac amyloidosis. He has a history of bilateral carpal tunnel surgery. Which test of the following would you order?

- 1) Tc- PYP scan, SPEP, UIEP
- 2) Serum light chains and serum and urine immunoelectrophoresis
- 3) CMR
- 5) Tc-99m PYP scan with serum and urine electrophoresis

Q4. A 77yo man with HFpEF has an echo suspicious
for cardiac amyloidosis. He has a history of bilateral
carpal tunnel surgery. Which test of the following
would you order?
<ul> <li>1) Tc- PYP scan , SPEP, UIEP</li> </ul>
0.0

- 2) Serum light chains and serum and urine immunoelectrophoresis
- 3) CMR
- 5) Tc-99m PYP scan with serum and urine immunoelectrophoresis

#### **SUMMARY**

- Amyloidosis is a multisystem disorder caused by the deposition of abnormal proteins in myocardial tissue and other organs
- Cardiac Amyloidosis (ATTR-CM) is an underrecognized cause of heart failure in the elderly population
- ATTR-CM can be identified by invasive techniques in most patients
- AL amyloidosis must be ruled out before the diagnosis of ATTR-CM is made
- Disease modifying therapy is available to stabilize what was once felt to be a terminal disease